Journal
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
Volume 28, Issue 2, Pages 90-94Publisher
ELSEVIER
DOI: 10.1016/j.ijantimicag.2006.05.021
Keywords
drotrecogin alfa activated; recombinant human activated protein C; sepsis syndrome; pathophysiology; drug therapy
Ask authors/readers for more resources
This review will summarise the relevant pathophysiology of sepsis, the rationale for treatment with recombinant human activated protein C and the evidence for and against its use, and will provide evidence-based recommendations for its administration. (c) 2006 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
